Another view: Maraviroc, a small molecule, seats deep "in the pocket" of its binding area, deforming the CCR5 receptor and preventing its proper function. Leronlmab, a large molecule, "floats" over a broader area of the receptor, allowing its normal signaling functions to continue.

At least that argument has been on this board.